G
G. Fatti
Researcher at University of Bologna
Publications - 5
Citations - 172
G. Fatti is an academic researcher from University of Bologna. The author has contributed to research in topics: Hepatocellular carcinoma & Cirrhosis. The author has an hindex of 3, co-authored 4 publications receiving 156 citations.
Papers
More filters
Journal ArticleDOI
The changing scenario of hepatocellular carcinoma over the last two decades in Italy.
V. Santi,Daniela Buccione,Antonio Di Micoli,G. Fatti,Marta Frigerio,Fabio Farinati,Paolo Poggio,Gianludovico Rapaccini,Maria Anna Di Nolfo,Luisa Benvegnù,Marco Zoli,Franco Borzio,Edoardo G. Giannini,Eugenio Caturelli,Maria Chiaramonte,Mauro Bernardi,Franco Trevisani +16 more
TL;DR: The survival improvement observed until 2001 was due to an increasing number of tumours diagnosed in early stages and in a background of compensated cirrhosis, and a growing and better use of locoregional treatments, and national policies aimed at implementing surveillance programmes for at risk patients.
Journal ArticleDOI
A new approach to the use of α-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis.
Maurizio Biselli,Fabio Conti,Annagiulia Gramenzi,M. Frigerio,Alessandro Cucchetti,G. Fatti,M D'Angelo,M. Dall'Agata,Eg Giannini,Fabio Farinati,Francesca Ciccarese,Pietro Andreone,Mauro Bernardi,Franco Trevisani +13 more
TL;DR: CAI achieves adequate sensitivity and NPV as a surveillance test for the early detection of HCC in cirrhosis as well as a validation group that considered 36 subsequent patients diagnosed with HCC, matched with contemporary cancer-free controls.
Journal ArticleDOI
Serum SCCA-IgM as a Predictor of Hepatocellular Carcinoma in Patients with Liver Cirrhosis
Daniela Buccione,G. Fatti,Andrea Gallotta,Elisabetta Loggi,Roberto Di Donato,Lilia Testa,Carlo Saitta,V. Santi,Antonio Di Micoli,Virginia Erroi,Marta Frigerio,Valentina Fazio,Antonino Picciotto,Alessandra Biasiolo,Francoise Degos,Patrizia Pontisso,Giovanni Raimondo,Franco Trevisani +17 more
TL;DR: SCCA-IgM serum measurement could permit implementation of a two step surveillance: an initial serological surveillance, based on the annual monitoring of this biomarker, and the conventional surveillance by semiannual US when SCCA+ve cirrhotic patients at low HCC risk becomes >200 AU/mL.
Journal ArticleDOI
F-9 Serum SCCA-IgM as a predictor of hepatocellular carcinoma (HCC) in patients with liver cirrhosis
Daniela Buccione,G. Fatti,Andrea Gallotta,Elisabetta Loggi,R. Di Donato,L. Testa,Carlo Saitta,V. Santi,A. Di Micoli,Valentina Fazio,Antonio Picciotto,Alessandra Biasiolo,Patrizia Pontisso,G. Raimondo,Franco Trevisani +14 more
Journal ArticleDOI
Cost-Effectiveness of Screening for Open Angle Glaucoma Compared With Opportunistic Case Finding
Alfonso Antón,David Serrano,Karen Nolivos,G. Fatti,Natasa Zmuc,Carlos Crespo,Toni Monleón-Getino,Katia Sotelo,Antonio Morilla,Virginia Garcia,Mercè Comas,Xavier Castells +11 more
TL;DR: In this paper , the authors evaluated the cost-effectiveness of glaucoma screening with imaging devices and telemedicine based on a screening campaign performed in Spain and concluded that the screening strategy implemented in their analysis was cost-effective compared with opportunistic case finding.